In the past three decades, survival outcomes of patients with early breast cancer (EBC) have notably improved, mainly due to early detection of the disease and advances in adjuvant treatments, such as endocrine therapy (ET), chemotherapy (CT), and anti-HER2 therapy. The gene discussed is ERBB2; the disease is breast carcinoma.